Frankfurt
10.09.26 | 08:05
0,086 Euro
+8,83 % +0,007
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | NextCell Pharma AB Q2 Sales Increase | 2 | RTTNews | ||
| 27.08. | NextCell Pharma AB: Interim Report second quarter 2026 | 133 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the second quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells... ► Artikel lesen | |
| 18.08. | NEXTCELL PHARMA AB: NextCell Selected for EU-Japan Biotech Business Mission and Strengthens Presence in Hong Kong | 1 | Cision News | ||
| 28.05. | NextCell Pharma AB: Interim Report first quarter 2026 | 325 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Interim report for the first quarter 2026. The report is available on the company's website: www.nextcellpharma.com. NextCells share... ► Artikel lesen | |
| 27.05. | Nextcell Pharma AB: Nextcell Pharma AB (publ) Annual General Meeting 2026 | 332 | GlobeNewswire (Europe) | On Wednesday, 27 May 2026, the Annual General Meeting of NextCell Pharma AB (publ), reg. no. 556965-8361 ("NextCell" or the "Company"), was held. A summary of the resolutions adopted at the Annual General... ► Artikel lesen | |
| 06.05. | FUJIFILM Biosciences and NextCell Launch Global Research-Use Stromal Cell Platform | 3 | Contract Pharma | ||
| 06.05. | NEXTCELL PHARMA AB: NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 4 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.05. | FUJIFILM Biosciences and NextCell Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media | 525 | Business Wire | Collaboration results in platform to help researchers overcome challenges in MSC research NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product... ► Artikel lesen | |
| 04.05. | NEXTCELL PHARMA AB: NextCell Pharma publishes Annual Report 2024/2024 | 1 | Cision News | ||
| 26.02. | NextCell Pharma AB: NextCell publishes Year-End Report 2024/2025 | 324 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) ("NextCell" or the "Company") publishes its Year-End Report for the extended financial year September 1, 2024 - December 31, 2025. The report is available on the company's... ► Artikel lesen | |
| 03.02. | NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes | 216 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with... ► Artikel lesen | |
| 21.01. | NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market | 209 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans in adult patients... ► Artikel lesen | |
| 15.01. | NextCell Pharma AB: Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes | 250 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation... ► Artikel lesen | |
| 02.12.25 | NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations | 249 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") has entered into a collaboration agreement with OptiCell Solutions AB ("OptiCell") regarding the handling, freezing, storage, and transport of cell products... ► Artikel lesen | |
| 20.11.25 | NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO | 537 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and... ► Artikel lesen | |
| 30.10.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025 | 242 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 18.09.25 | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 261 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,030 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,360 | -2,75 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,050 | -5,94 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -3,36 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 118,49 | +2,65 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| BEAM THERAPEUTICS | 24,190 | -3,91 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,040 | +1,98 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| COGENT BIOSCIENCES | 33,660 | -1,43 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,540 | -0,71 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| TYRA BIOSCIENCES | 23,540 | +6,95 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ALUMIS | 9,900 | +1,02 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| IMMUNOVANT | 37,790 | -2,48 % | Immunovant, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 339,14 | -1,78 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TARSUS PHARMACEUTICALS | 81,55 | -1,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen |
NEXTCELL PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,086 Euro und damit +8,83 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.